Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Central Nervous System Neoplasms 3Brain Neoplasms 3Glioma 2Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Skin Neoplasms 1Sarcoma 1Pinealoma 1Neuroma, Acoustic 1Neoplasms, Germ Cell and Embryonal 1Mouth Neoplasms 1Meningioma 1Melanoma 1Medulloblastoma 1Glioblastoma 1Ependymoma 1Craniopharyngioma 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Astrocytoma 1

Interventions

Doxorubicin 141Ifosfamide 85Radiotherapy 80Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 39Etoposide 39Docetaxel 39Vincristine 37Cisplatin 35Trabectedin 32Nivolumab 32Irinotecan 26Magnetic Resonance Spectroscopy 25Carboplatin 25Temozolomide 23Ipilimumab 22Bevacizumab 20Radiation 19Surgical Procedures, Operative 18Granulocyte Colony-Stimulating Factor 18Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17Biopsy 17eribulin 16anlotinib 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma × tozuleristide × Clear all
NCT02464332 2016-05-26

Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

Blaze Bioscience Inc.

Phase 1 Withdrawn
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡